Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such a… Read more
Viva Biotech Holdings (VBIZF) - Total Liabilities
Latest total liabilities as of June 2025: $2.98 Billion USD
Based on the latest financial reports, Viva Biotech Holdings (VBIZF) has total liabilities worth $2.98 Billion USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Viva Biotech Holdings - Total Liabilities Trend (2016–2024)
This chart illustrates how Viva Biotech Holdings's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Viva Biotech Holdings Competitors by Total Liabilities
The table below lists competitors of Viva Biotech Holdings ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Garware Technical Fibres Limited
NSE:GARFIBRES
|
India | ₹5.79 Billion |
|
ECOVE Environment Corp
TWO:6803
|
Taiwan | NT$9.15 Billion |
|
SOLiD Inc
KQ:050890
|
Korea | ₩183.20 Billion |
|
Prism Johnson Limited
NSE:PRSMJOHNSN
|
India | ₹54.90 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥222.24 Million |
|
Takamatsu Construction Group Co., Ltd.
PINK:TAKMF
|
USA | $144.69 Billion |
|
Krispy Kreme Inc
NASDAQ:DNUT
|
USA | $1.91 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Viva Biotech Holdings's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viva Biotech Holdings's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viva Biotech Holdings (2016–2024)
The table below shows the annual total liabilities of Viva Biotech Holdings from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.23 Billion | -14.03% |
| 2023-12-31 | $3.76 Billion | -12.84% |
| 2022-12-31 | $4.32 Billion | +4.47% |
| 2021-12-31 | $4.13 Billion | -6.05% |
| 2020-12-31 | $4.40 Billion | +3522.38% |
| 2019-12-31 | $121.39 Million | -56.32% |
| 2018-12-31 | $277.90 Million | +459.82% |
| 2017-12-31 | $49.64 Million | +96.06% |
| 2016-12-31 | $25.32 Million | -- |